US WORLD Meds: PROGO Study

What is the PASSAGE Study?

A Prospective, Observational Study to Evaluate Changes in Non-Motor Symptoms and other Clinical Outcome Assessments of Parkinson’s Disease Patients Treated with XADAGO (safinamide) Tablets

Why is this research being done?

As a patient with Parkinson’s disease (PD), your doctor has prescribed XADAGO (safinamide) for you to take along with your other medications, such as carbidopa/levodopa. XADAGO is an FDA-approved drug to treat patients like yourself with PD.

You are being asked to take part in a study that is being sponsored by US WorldMeds, LLC. You are being asked to be in this study because you are taking XADAGO. They want to collect information about the non-motor symptoms and treatment experience of patients who have PD and are receiving XADAGO (safinamide). Non-motor symptoms can include a wide variety of problems like: mood disorders; changes in memory or thinking; sleep difficulties; constipation; pain; fatigue; urinary, weight and sexual problems; loss of sense of smell; and impulsive control disorders such as binge eating and excessive shopping or gambling. To collect this information, US WorldMeds has created a research study database. This research database is a way of confidentially collecting and keeping information about all patients who take part in this study

Each person who joins this research study will have his/her information collected for the study database for at least 6 months but possibly 12 months (if you are eligible and want to participate in the 6-month extension period).

Study Investigators: Dr. Denis Ostrovskiy and Dr. Vincent DeOrchis